ResearcherNanjing Drum Tower HospitalActive in the last 2 years

Qin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4955-1490; OpenAlex author ID A5100675592. Sources: OpenAlex.

Their work

Papers: 1
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2024: 1 paper

Papers 1

Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic cancer: a single-arm, phase II clinical t… Co-author DOI 10.1007/s00262-024-03744-z ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Liang Qi · 1 shared paper, 2024 · strength 0.20
- Paper Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic c… DOI 10.1007/s00262-024-03744-z ↗
Juan Du · 1 shared paper, 2024 · strength 0.20
- Paper Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic c… DOI 10.1007/s00262-024-03744-z ↗
Juan Liu · 1 shared paper, 2024 · strength 0.20
- Paper Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic c… DOI 10.1007/s00262-024-03744-z ↗
Fan Tong · 1 shared paper, 2024 · strength 0.20
- Paper Hypofractionated radiotherapy plus PD-1 antibody and SOX chemotherapy as second-line therapy in metastatic pancreatic c… DOI 10.1007/s00262-024-03744-z ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.